Gilead Sciences Unusual Options Activity For September 20
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
ENDPOINTS NEWS2d
Yuhan ends can­cer project with J&J as it signs API deal with Gilead on HIV drugs
Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...
FiercePharma2d
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Korea Joongang Daily on MSN2d
Yuhan inks $80.9 million deal with Gilead Sciences for HIV ingredients
Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...
Gilead Sciences Inc. stock rises Thursday, still underperforms market
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...
bovnews3d
Gilead Sciences, Inc. (GILD) Stock: Unveiling Its Hidden Strengths
Raymond James has recently raised Gilead Sciences, Inc. (GILD) stock to Outperform rating, as announced on July 8, 2024, according to Finviz. Earlier, on May 1, 2024, Maxim Group had reiterated the ...